Michael Rafii, Md, Phd

This study is testing whether the drug donanemab can reduce the buildup of a harmful protein called amyloid in the brains of adults with Down syndrome. About 60 participants, aged 35-50, will receive monthly infusions of either donanemab or a placebo for one year, followed by an …